Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?

References

• Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M. 2016. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 5:182–191. doi:10.1002/cam4.576.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, et al. 2011. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364:1995–2005. doi:10.1056/NEJMoa1014618.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, et al. 2013. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369:213–223. doi:10.1056/NEJMoa1213755.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al. 2012. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197. doi:10.1056/NEJMoa1207506.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al. 2010. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 376:1147–1154. doi:10.1016/S0140-6736(10)61389-X.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al. 2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. doi:10.1056/NEJMoa040720.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, A’Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, et al. 2009. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 27:3742–3748. doi:10.1200/JCO.2008.20.0642.
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, et al. 2012. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. 97:507–516. doi:10.1210/jc.2011-2189.
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, et al. 2008. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 26:4563–4571. doi:10.1200/JCO.2007.15.9749.
   PubMed Web of Science ®Google Scholar
• Thakur A, Roy A, Ghosh A, Chhabra M, Banerjee S. 2018. Abiraterone acetate in the treatment of prostate cancer. Biomed Pharmacother. 101:211–218. doi:10.1016/j.biopha.2018.02.067.
   PubMed Web of Science ®Google Scholar
• Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, et al. 2016. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 17:1306–1316. doi:10.1016/S1470-2045(16)30173-5.
   PubMed Web of Science ®Google Scholar
• Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A, Smith MR, Agrawal M, Dicker AP, et al. 2018. Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. Experience from an expanded access program. Oncologist. 23:193–202. doi:10.1634/theoncologist.2017-0413.
   PubMed Web of Science ®Google Scholar
• Shore ND, Tutrone RF, Mariados NF, Nordquist LT, Mehlhaff BA, Steere KJ, Harrelson SS. 2018. eRADicAte: a prospective evaluation combining radium-223 dichloride and abiraterone acetate plus prednisone in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 16:149–154. doi:10.1016/j.clgc.2017.10.022.
   PubMed Web of Science ®Google Scholar
• Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, et al. 2019. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20:408–419. doi:10.1016/S1470-2045(18)30860-X.
   PubMed Web of Science ®Google Scholar
• Dalla Volta A, Formenti AM, Berruti A. 2019. higher risk of fragility fractures in prostate cancer patients treated with combined radium-223 and abiraterone: prednisone may be the culprit. Eur Urol. 75:894–895. doi:10.1016/j.eururo.2019.01.026.
   PubMed Web of Science ®Google Scholar
• Cursano MC, Santini D, Iuliani M, Paganelli G, De Giorgi U. 2019. Early use of abiraterone and radium-223 in metastatic prostate cancer. Lancet Oncol. 20:e228. doi:10.1016/S1470-2045(19)30310-9.
   PubMedGoogle Scholar
• Iuliani M, Pantano F, Buttigliero C, Fioramonti M, Bertaglia V, Vincenzi B, Zoccoli A, Ribelli G, Tucci M, Vignani F, et al. 2015. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget. 6:12520–12528. doi:10.18632/oncotarget.3724.
   PubMed Web of Science ®Google Scholar
• Tombal B, Loriot Y, Saad F, McDermott T, Rodriguez-Vida A, Nole F, Fournier B, Collette L and Gillessen S. 2019. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis. J Clin Oncol. 37: suppl_abs 5007 (oral presentation). doi:10.1200/JCO.2019.37.15_suppl.5007.
   Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, et al. 2011. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 377:813–822.
   PubMed Web of Science ®Google Scholar
• Saad F, Sternberg CN, Mulders PFA, Niepel D, Tombal BF. 2018. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. Cancer Treat Rev. 68:25–37.
   PubMed Web of Science ®Google Scholar
• Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. 2001. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 84:1126–1134.
   PubMed Web of Science ®Google Scholar
• Hegemann M, Bedke J, Stenzl A, Todenhofer T. 2017. Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Ther Adv Urol. 9:81–88.
   PubMed Web of Science ®Google Scholar